Study of Maintenance Pazopanib, Radiation Therapy, and Selinexor for Treating Non-Rhabdomyosarcoma Soft Tissue Sarcoma in Patients Up to 30 Years Old

What this Trial Is About

Researchers are studying treatment strategies for patients diagnosed with non-rhabdomyosarcoma soft tissue sarcoma NRSTS, focusing on different risk groups including low, intermediate, and high-risk categories. The study evaluates combinations of surgery, chemotherapy drugs ifosfamide, doxorubicin, pazopanib, selinexor, and radiation therapy to assess outcomes such as event-free survival, maximum tolerated dose, and treatment-related toxicities. Additional research goals include understanding drug pharmacokinetics, tumor molecular features, and long-term health effects related to cancer and its treatment. Participants receive risk-adapted therapies based on their tumor grade, size, and surgical margins. Low-risk patients may undergo surgery alone with monitoring, while intermediate- and high-risk groups receive combinations of chemotherapy, radiation therapy, and maintenance treatment with pazopanib. Radiation is delivered daily over 5 to 6 weeks starting 3 to 6 weeks after surgery. Selinexor is studied for high-risk patients as an oral medication taken once on day 3. Treatment plans may include induction chemotherapy cycles, surgery timing, and consolidation therapies tailored to tumor resectability and molecular characteristics. Throughout the study, participants undergo regular assessments including imaging, pharmacokinetic sampling, and cardiac monitoring to evaluate treatment response and safety. Researchers measure event-free survival over up to 9 years and determine recommended dosing levels. Tumor samples may be analyzed using advanced genetic and molecular tools. Participants are monitored for side effects, tumor recurrence, and overall health, with follow-up continuing for several years to capture long-term outcomes and treatment impacts.

NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)